Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF-Reference-Cited by-同舟云学术

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF

Published:2021-08 Issue:8 Volume:9 Page:578-589
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Requena-Ibáñez Juan Antonio,Santos-Gallego Carlos G.,Rodriguez-Cordero Anderly,Vargas-Delgado Ariana P.,Mancini Donna,Sartori Samantha,Atallah-Lajam Farah,Giannarelli Chiara,Macaluso Frank,Lala Anuradha,Sanz Javier,Fuster Valentin,Badimon Juan José

Funder

Fundación Alfonso Martín Escudero

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Predictors of new-onset heart failure differences in preserved versus reduced ejection fraction;Ho;Circ Heart Fail.,2013

2. Echocardiographic epicardial adipose tissue thickness for risk stratification of patients with heart failure;Parisi;Front Physiol.,2020

3. Inflammation in heart failure: JACC State-of-the-Art Review;Murphy;J Am Coll Cardiol.,2020

4. Increased epicardial adipose tissue volume correlates with cardiac sympathetic denervation in patients with heart failure;Parisi;Circ Res.,2016

5. Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk;Villasante Fricke;Int J Molec Sci.,2019

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits;Cellular Signalling;2024-10

2. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

3. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

4. Metabolism and bioenergetics in the pathophysiology of organ fibrosis;Free Radical Biology and Medicine;2024-09

5. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions;American Journal of Physiology-Cell Physiology;2024-09-01